ImmunoBrain Checkpoint

Company Overview

Snapshot

Founded in February 2015 by Prof. Michal Shwartz, ImmunoBrain Checkpoint is a biopharmaceutical company with 11–50 employees. The company has secured funding across one disclosed round from one investor. In March 2026, ImmunoBrain Checkpoint announced plans to present topline Phase 1b clinical data for its immune checkpoint treatment in Alzheimer's disease at ADPD 2026.

Business overview

ImmunoBrain Checkpoint (IBC) is a biopharmaceutical company focused on developing disease-modifying immunotherapies for neurological disorders. The company's core technology targets immune checkpoint pathways, with its lead programs specifically addressing Alzheimer's disease by blocking the PD-1/PD-L1 immune checkpoint pathway. IBC operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology, and serves markets related to biotechnology and pharmaceuticals.

Strategic signal

In March 2026, ImmunoBrain Checkpoint announced its intention to present topline Phase 1b clinical data for its immune checkpoint treatment in Alzheimer's disease at ADPD 2026. This signals significant progress in the company's clinical development pipeline and provides a crucial validation point for its novel approach to neurodegenerative disorders, potentially attracting further investment and partnerships in the biopharmaceutical industry.

Company Intelligence Q&A

What is ImmunoBrain Checkpoint's primary focus?

ImmunoBrain Checkpoint is a biopharmaceutical company dedicated to developing disease-modifying immunotherapies for neurological disorders by targeting immune checkpoint pathways.

When was ImmunoBrain Checkpoint founded and by whom?

ImmunoBrain Checkpoint was founded in February 2015 by Prof. Michal Shwartz.

What is the latest clinical development from ImmunoBrain Checkpoint?

In March 2026, ImmunoBrain Checkpoint announced plans to present topline Phase 1b clinical data for its immune checkpoint treatment in Alzheimer's disease at ADPD 2026.

Who recently joined ImmunoBrain Checkpoint's Board of Directors?

In October 2025, Dr. Francis S. Collins joined ImmunoBrain Checkpoint's Board of Directors. In September 2025, Rochelle Walensky, MD, MPH, also joined the Board of Directors.

Which company obtained rights to ImmunoBrain Checkpoint's Alzheimer's research?

In June 2017, Lundbeck, a global pharmaceutical company, obtained the rights to ImmunoBrain Checkpoint's research into treatment for Alzheimer's disease.